Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab, subcutaneous co-formulations of pertuzumab and rastuzumab, and their use in the treatment of cancer. [Selection diagram] Fig. 6